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Abstract So-called ‘immunological memory’ is, in my
view, a typical example where a field of enquiry, i.e. to
understand long-term protection to survive reexposure to
infection, has been overtaken by ‘l’art pour l’art’ of ‘basic
immunology’. The aim of this critical review is to point out
some key differences between academic text book-defined
immunological memory and protective immunity as
viewed from a co-evolutionary point of view, both from the
host and the infectious agents. A key conclusion is that
‘immunological memory’ of course exists, but only in
particular experimental laboratory models measuring
‘quicker and better’ responses after an earlier immuniza-
tion. These often do correlate with, but are not the key
mechanisms of, protection. Protection depends on pre-
existing neutralizing antibodies or pre-activated T cells at
the time of infection—as documented by the importance of
maternal antibodies around birth for survival of the off-
spring. Importantly, both high levels of antibodies and of
activated T cells are antigen driven. This conclusion has
serious implications for our thinking about vaccines and
maintaining a level of protection in the population to deal
with old and new infectious diseases.
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Introduction
In the beginning was the fact that, once recovered from an
infection, the patient was resistant for life to disease by
the same infection. This, we call immunity. But since the
1880s, with the beginning of modern immunology, the
term immunological memory was borrowed from ‘con-
ventional’ (neurological) memory to seemingly explain this
fact. We still do not understand whether ‘conventional’
brain memory is due to once perceived or thought =
always remembered, versus repeatedly reencountered,
recollected, or dreamed. This controversy is the subject of
this review on academic immunological memory versus
immunity.
Immunological memory, specificity, and tolerance are
three key parameters that immunologists study. Many have
reviewed some aspects of this crucial triad of immunity and
have voiced serious concerns, not only about the use of
these words but also about their implied meaning [1–7].
Immunological memory is defined in text books as follows
[2, 3]: ‘The ability of the immune system to respond more
rapidly and effectively to pathogens that have been
encountered previously, and that reflects the pre-existence
of clonally expanded populations of antigen specific lym-
phocytes. Memory responses which are called secondary
depending on the number of exposures to antigens also
differ qualitatively from primary responses. This is par-
ticularly clear in the case of the antibody response, where
the characteristics of antibodies produced in secondary and
subsequent responses are distinct. Specific memory is
maintained by distinct populations of long-lived memory
cells, that can persist without antigen’ [2]. Another defi-
nition states [3]: ‘Once the immune system has recognized
and responded to an antigen, it exhibits immunological
memory’. A second encounter with the same antigen
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induces a heightened state of immune reactivity. Because
of this attribute, the immune system can confer life-long
immunity to many infectious agents after an initial
encounter’. The alternative interpretation, that lymphocytes
are repeatedly stimulated by antigen re-exposure within the
host or from the outside, appears to have been settled in
favor of the former type in most immunologists’ mind [1–
6]). The key question is, however, whether this ‘immuno-
logical memory’ (i.e. accelerated and heightened response)
is good enough to protect the host from either new acutely
lethal infections or re-infections for better survival of the
species? There is no doubt about experimental documen-
tation of academically defined immunological memory. If a
mouse is primed with sheep red blood cells, then a second
injection of red cells will reveal an accelerated and
heightened response. This also applies to bovine serum
albumin, nuclear protein of virus, or classical carrier hapten
molecules [1–6]. While accelerated and better responses
often correlate with protective immunity, they are alone
definitely not sufficient [7–9]. The pre-existing titer of
protective antibody or activity of highly activated effector
T cells at the time of infection are generally accepted to
determine whether or not a host is protected, or can control,
an infection better than a naı¨ve host [8, 10, 11]. In addition,
it must be kept in mind that so-called innate or natural
immunity is a very important basis for resistance to
infection; this includes interferon, Toll-like receptor med-
iated effects, and so-called natural (non-intentionally)
induced antibodies in serum [12]. The latter are highly
specific protective antibodies as defined by neutralization
assays and by protection. These natural antibodies simply
reflect the genetically determined, existing spectrum of the
specific B cell repertoire. This includes serotypically
defined viral-, bacterial-, or toxin specificities. By defini-
tion, such natural antibodies are not cross-reactive but are
serotypically specific as formally documented for neutral-
izing antibodies against viruses [12].
Why should higher vertebrates need ‘immunological
memory’, be it for B cells or T cells? I have been arguing
repeatedly [6–9] that if the first infection kills the host,
there is no longer any need for immunological memory.
Alternatively, if the host can survive the first infection, this
indicates that its immune system is capable of dealing with
that particular type of infection efficiently, at least during
the crucial period necessary for procreation. In evolution,
such efficiency is defined by the fact that some percentage
of the species survives a primary infection in the absence of
a vaccine or any previous exposure. This has been well
documented for the middle ages when smallpox first
arrived in Europe with mortality rates of up to 80 or 90 %
[13], or the more recent myxomatosis exposure of Euro-
pean rabbits in Australia [14].
I summarise as follows: General parameters of
immunity
1. Infections by cytopathic/toxic, i.e. acutely lethal
agents are controlled by innate plus adaptive resis-
tance mechanisms [1–8]. Non-cytopathic persistent
infections are non-pathogenic if an immune response
is avoided or reduced [6, 9, 15]; this usually results
from T cell deletion [15] and neutralizing antibody
escape by mutation [16]. Remember, however, very
low levels of residual infection keeps immunity
active by ‘infection immunity’ [17–20].
2. The immune system only reacts with a timely IgM or
IgG response if antigen reaches secondary lymphoid
organs [21–23].
3. The best correlate of protection against infectious
diseases is the pre-existing neutralizing or protective
antibody level at the time of exposure to the infection
[6–11]. This is best illustrated by the absolute
requirement of maternal antibodies in newborns
‘and infants’ serum and mucosals (from mothers
milk) for survival of offspring during the phase of
neonatal and early childhood immuno-incompetence
[8, 24].
4. B cell IgM responses against repetitive multimeric
antigens or monomers plus Tlr signals are made in
the absence of T help [25–28]. These IgM responses
have a short half-life of *24 h, and of course have a
high avidity and superb complement activation
capacity. IgA production in the mucosa lamina
propria is T help and secondary lymphoid organ
independent [29]. For IgE, these rules are less clear:
while specific IgE is strictly T help dependent, hyper-
IgE is not [30, 31].
5. ELISA antibody responses usually binding at 105–
106 M-1 represent highly frequent B cells (10-2–
10-3) [32–34], whereas B cells producing neutralizing
or protective antibodies with affinities of[109 M-1 in
mice or[1010 M-1 in humans are rare\10-5 [35, 36].
6. Affinity maturation, i.e. improvement of binding
qualities by somatic mutation is a slow process
requiring weeks to months. Obviously, acutely lethal
infections that are controlled immunologically must
be reflected in the basic antibody (or T cell)
repertoire available at the time of infection [12,
35]. In contrast, non-cytopathic infections that persist
may well induce initially low affinity, non-protective
antibodies that over time improve by a process of
somatic mutation. An example of such a process has
been documented for the neutralizing antibody
response against LCMV [16, 37–39]. Usually, this
process is illustrated with immunological text book
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cases using nitrophenyl- (NP) or oxazolon-specific
IgG responses [40, 41]. However, some of these
examples are misleading, because it is usually not an
improved original type of anti-NP antibody that binds
better to NP. Instead, a newly selected antibody with
better binding capacities comes up, and this corre-
lates with a special groove in the binding site of this
antibody, into which the small NP fits well. In this
context, it is important to remember that relevant
biologically active and protective antigenic sites
comprise about 7–15 amino acids for contact inter-
actions with a neutralizing antibody [26, 36]. In
contrast, academic haptens such as NP are equivalent
to only one amino acid. Therefore, it is not surprising
that the rules derived from studying hapten-specific
antibody responses do not apply to immunity [20,
34]. Also, the concept that highly specific antibodies
show broad cross-reactivity is true for small phenyl-
group-type haptens or ELISA-measured antibodies to
plastic bound proteins, but is not true for complex but
well-defined biologically relevant neutralizing anti-
genic sites [20, 34]. Thus, ‘cross reactivity’ is seen
with antibody binding assays measuring low affinity/
avidity antibodies, but not with serotype-specific
protection assays.
7. The classical carrier hapten priming effect is valid for
hapten-specific ELISA antibody responses but not for
the serotype-specific neutralizing antibody responses
against infectious agents. In the first case, where B
cell frequencies are very high (*10-2) [32, 33, 44,
45], T help is usually limiting. In the second case of
biologically relevant situations, T helper cells are
always in excess and B cell frequency is limiting
(*10-5) [20, 26, 34, 46]. I am not contesting the old
experimental data of the classical carrier hapten
experiments, I simply question their biological rele-
vance. In view of the fact that the only correlate of
protection against acute potentially lethal infections
is the pre-existing level of neutralizing antibodies (or
of already activated T cells) at the time of infection,
text book-defined immunological memory—quicker
and better [1–5]—is too slow to protect [6–8, 10].
8. Protective antibodies against serotypically defined
virus or bacteria strains are non-cross-reactive by
definition [6, 7, 47], and experimental- or epidemi-
ological evaluation has revealed that cross-reactive
antibodies are not protective. Therefore, attempts to
raise cross-protective antibodies against Influenza
viruses [48–50] or HIV clades [51–53] is useless, has
failed so far, and will fail in the future. Rare viruses
(or bacteria?) do not comply with this simple rule,
e.g., Dengue viruses [54] exhibit defined, but
partially overlapping, serotypes correlating with the
not yet understood complication of hemorrhagic
fever upon certain kinds of cross-reexposure.
9. Spontaneous or not intentionally induced neutralizing
antibodies against acute cytopathic agents are spe-
cific and not simply a cross-reactive background [12].
They play a major role in reducing early hematoge-
nically spreading antigen. The neutralizing titer of
naı¨ve serum against acute cytopathic virus infections
is often around 1:30. Note that the difference
between spontaneous and protective serum titer (i.e.
[1:500) is only about 10- to 30-fold. Interestingly,
against non-cytopathic viruses, such natural antibody
titers usually cannot be measured [12, 16, 38, 39]. In
fact, it has been found that protective neutralizing
antibody responses against such persistingly non-
cytopathically infecting viruses (LCMV, HIV, etc.)
must undergo slow affinity maturation during which
mutational escape is possible (e.g., [16, 38]).
10. Protection requires minimal affinity 10-9 in mice and
10-10–10-11 in humans and concentration [1 lg/ml
of protective neutralizing IgG antibody [36].
11. Plasma cells producing protective antibodies are
relatively short-lived (1–5 days). Once B cells are
fully induced and matured to plasma cells, they get
deleted (e.g., [20, 38]). This result of course is in
contrast to many studies using ELISA-type antibody
responses [5, 55, 56] against haptens [1, 5, 33, 34],
but also against viral antigens irrelevant for protec-
tion, such as nuclear protein [20, 55]. However, when
the serotype specificity-constraints of the antibody
produced by plasma cells are observed, experiments
and epidemiology clearly show that only recently
activated B cells become neutralizing antibody-pro-
ducing plasma cells which exhibit a half-life of
somewhere between 1 and 5 days [20]. This short
half-life is a safe guard against autoantibody-depen-
dent autoimmunity. Therefore, increased B cell
frequencies (or memory B cells) are antigen inde-
pendent, while maintenance of increased neutralizing
antibody levels are antigen dependent [20].
12. Avoidance or delay of a neutralizing antibody
response arises from: (1) low precursor B cell
frequency [17, 38, 39, 57], (2) requirement of affinity
maturation [16, 38, 39, 42], (3) immunopathological
destruction of follicle organization in secondary
lymphatic tissues [23], (4) variability of the protec-
tive antigen [16, 43, 58], and (5) excess T help
causing hyper-IgG responses [59].
13. Sufficient levels of protective antibody must be
transferred from mother to offspring via placenta
(IgG) and milk (IgA/IgG) to protect the offspring
during the 1–2 years after birth against acute cyto-
pathic (childhood) infections. Attenuation of these
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infections by transferred maternal antibody represents
the physiological equivalent of vaccination [8, 24].
14. Epidemiologically active conditions are essential to
establish active herd immunity against childhood
infections [6–8, 11, 24]. It is important that offspring
get exposed to epidemiologically active infection
during the post-natal period where maternal antibod-
ies are still present to promote enhanced survival and
establish acquired immunity [24].
15. Successful vaccines protect humans by neutralizing
antibodies via reexposure and immune complexes [6–9,
11, 60]. In contrast, we still lack efficient vaccines that
maintain activated T cell responses (and/or neutralizing
antibody responses) against highly variable agents for a
long time as is necessary against HIV, HCV, malaria,
TB, and many other infections [17, 18, 27, 57, 60].
16. Antigen dependence of protection is often masked by
antigen persisting at very low levels in the herd or in
the individual, often extralymphatically and some-
times in unconventional forms. This includes
persistence of dormant non-replicating infections or
crippled virus ‘persisting’ in the host [6, 7, 11, 60–64]
(e.g., Herpes viruses, measles virus) or of DNA forms
of conventionally integrated retroviral RNA viruses
[53], or through an unconventional DNA form
expressed with the help of retroviral elements in the
genome of the host [65, 66]. Reexposure from outside
is very commonly unrecognized, particularly for
mucosal infections (reviewed in [1–9, 11, 47]).
17. Therefore, immunity represents low level antigen-
driven immune responses in absence of overt immu-
nopathology in the herd [6–9, 15]. This is best
illustrated by antigen derived from reexposure from
the outside or the inside of the host by immune
complexes [60] (representing antigen depots of
several months up to probably years). Low level
persistent infections, such as herpes virus infections,
TB, leprosy, or HIV constantly reboost immunity.
Remember, in the absence of a TB granuloma,
protective T cell immunity fades within 1–2 years,
e.g., after BCG immunization, while on the other
hand, too many or extensive granulomas eventually
cause lethal tuberculosis.
Discussion
The term immunological memory was originally coined to
seemingly understand protective immunity and to explain
why and how vaccinations work. Because this definition and
the experiments used to support this definition usually had
nothing to do with infections (or used infectious disease
antigens to study immune memory independent of protec-
tion), the apparent correlation was seriously misused, even
after improved understanding of both infections and of
immune responses became apparent (e.g., [6, 7, 60–64]. The
present review is yet another attempt to revise generally held
views and to resolve serious discrepancies between the aca-
demic ideas on immunological memory and the fact of
immunity, i.e. long-term protection against lethal infections.
Because words matter and because the immunological com-
munity is generally not interested in infectious diseases, the
false use of ‘memory’ to explain protective immunity persists.
The view summarized here, of course, has serious
implications not only on the general public’s understanding
of vaccines and public health but also has a great impact on
politics and public support of science. Why do I point this
out? Let us assume certain childhood infections against
which we have excellent vaccines are now well controlled,
but at the ‘cost’ of reducing epidemiologically circulating
wild-type (or live vaccine strain) infections to maintain
herd immunity [8, 11, 24, 47]. This is now becoming more
obvious as the live-attenuated Sabin vaccine gets phased
out (because of the emergence of virulent revertants) [11,
47] and is being replaced by the inactivated Salk vaccine.
While until recently the live-attenuated Sabin vaccine
repeatedly re-vaccinated the herd, in the future this will not
happen. Of course, if there is complete elimination of polio
this may not matter. However, unless this has been
achieved, any new outbreak of polio would become a great
potential disaster, because of exposure of adults and of
newborns who possess a level of protection that is insuf-
ficient to attenuate initial infections, and therefore cannot
allow for disease-free survival of virtually all members of
the species. It is now being observed that very early
infection with rubella or whooping cough [67, 68] has
serious consequences in babies of mothers who had been
vaccinated against these agents [with presumably relatively
low protective (not necessarily ELISA) antibody titers] in
the now altered epidemiological situation—i.e. with non-
replicating vaccine agents and absent or rare re-exposure in
the herd in the absence of revaccination. While these are
early observations, they at least signal epidemiological
conditions where circulating infections and herd immunity
may become so low that general maintenance of protection
by herd immunity plus vaccinations is not any longer
guaranteed [24], unless revaccinations are implemented
frequently for perhaps the entire life span.
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